Skip to main content
Liying Zhang on Muck Rack

Liying Zhang

As seen in: Color Research & Application, Nature, Wiley Online Library, ScienceDirect, Frontiers, MDPI, Taylor & Francis Online, ACS Publications, Diagnostic Pathology, Royal Society of Chemistry and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Liying

Contact Liying, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Prognostic analysis of epithelial ovarian cancer patients with normal CA125 level: a population-based comparative study

|
By Liying Zhang, Yibao Huang, Zhijun Yang, Chuanzhong Liu, Haijuan Shi
| Nature Verified
Abstract The epithelial ovarian cancer (EOC) with normal CA125 level is relatively rare. This study aims to develop a nomogram model for predicting the overall survival (OS) of EOC patients with normal CA125 level. A total of 13,068 patients with epithelial ovarian cancer (EOC) were extracted from the SEER database, and an additional 138 patients were recruited from our hospital as an external validation cohort.
Open in Who Shared Issue with article?

Anlotinib combined with neoadjuvant chemotherapy for HR+/HER2− breast cancer (ACNTBC): a prospective, single-arm, single-center phase II clinical study with real-world validation

|
By Jiajun Ding, Huimin Meng, Yidi WANG, Mengxuan Li, He Chen, Cong Fan, Shuai Wang, Liying Zhang, Lei Shang, Jing Kong, Jing Fan, Ting Wang, Haoyi Zi
| Nature Verified
Abstract Despite being an option for high-risk or inoperable cases, existing neoadjuvant therapies for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer yield suboptimal pathological responses, necessitating novel strategies. This prospective, phase II ACNTBC trial (NCT05558722) investigated the efficacy and safety of combining anlotinib with chemotherapy as a neoadjuvant treatment for HR+/HER2− breast cancer.
Open in Who Shared Issue with article?

Multiscale Carbonā€Reinforced Thermoplastic Foam Composites for Tunable EMI Shielding and Robust Mechanical Strength

|
By Dongxu Kang, Yinle Qin, Haobin Li, Lele Cheng, Keqing Han, Liying Zhang, Muhuo Yu, Zeyu Sun
| Wiley Online Library Verified
Multiscale Carbonā€Reinforced Thermoplastic Foam Composites for Tunable EMI Shielding and Robust Mechanical Strength - Kang - Polymer Composites - Wiley Online Library
Open in Who Shared Issue with article?
See all 73 licensed articles (76 Total)